Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Xiaochun Zhang, Min‐Hee Ryu et al.|The Lancet Oncology|2023Cited by 614
Immunotherapy in NSCLC: A Promising and Revolutionary WeaponChristian Rolfo, Mauricio Mahave, Christian Caglevic et al.|Advances in experimental medicine and biology|2017Cited by 143